Alaa Halawa

Alaa Halawa is a seasoned executive with extensive experience in the venture capital and biotechnology sectors. Currently serving as the Executive Director and Head of US Ventures at Mubadala since March 2017, Alaa is also involved as a Board Member at Neumora, xilis, Alloy Therapeutics, and Pretzel Therapeutics, as well as holding roles as a Board Observer at EQRx and Outpace Bio. Additionally, Alaa is an investor in notable companies including Science 37, Ciitizen, and Lyell Immunopharma. Educational qualifications include an MBA in Business Administration and Management from Cornell University and a B.Sc. in Electrical Engineering from the University of Jordan.